Pharmaceutical 3D Dispensing for High-API Direct Extrusion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing additive manufacturing techniques for pharmaceutical products, such as FFF and HME, are limited by the need for pre-prepared drug-loaded filaments, which restrict drug loading, require specific mechanical and dimensional properties, and limit formulation choices due to processing constraints.
Innovation Solution
A dispensing apparatus and method that allows direct extrusion and dispensing of pharmaceutical compositions without pre-prepared filaments, using a system with a hopper, extruder, dispensing apparatus, and control unit to regulate temperature, pressure, and flow, enabling higher API-to-polymer ratios and wider formulation ingredients.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If pre-prepared drug-loaded filaments are used in FFF 3D printing, then the mechanical and dimensional properties of the filament can be controlled, but the drug loading capacity is limited and formulation choices are restricted
Solution Approach 1:
The patent removes the intermediate filament preparation step from the manufacturing process. Instead of creating drug-loaded filaments separately and then printing, the system directly extrudes and deposits pharmaceutical compositions layer-by-layer, eliminating the need for pre-formed filaments and their associated constraints on drug loading and formulation
Solution Approach 2:
The system performs preliminary mixing of polymer and API in the hopper before extrusion, ensuring homogeneous distribution of the active pharmaceutical ingredient throughout the composition. This preliminary action allows for higher drug loadings while maintaining formulation flexibility, as the mixing occurs directly in the printing system rather than requiring pre-formed filaments
2Manufacturing precision
If HME is used to create filaments with specific dimensional properties, then the FFF printer mechanics can operate properly, but the processing complexity increases and productivity decreases
Solution Approach 1:
The patent combines the extrusion and 3D printing operations into a single integrated process. The extruder directly feeds the pharmaceutical composition to the printing nozzle, eliminating the separate HME filament production step. This merging maintains dimensional control through direct extrusion parameters while significantly improving productivity by removing an intermediate manufacturing stage
Solution Approach 2:
The system segments the manufacturing process into direct extrusion and layer deposition functions within a single integrated apparatus. Rather than requiring separate HME and FFF operations, the patent divides the extrusion mechanism to serve both filament formation and direct printing functions, reducing overall process complexity and increasing efficiency
3Quantity of substance
If filaments with high API content are prepared, then higher API-to-polymer ratios can be achieved, but the filament mechanical properties deteriorate and processing becomes difficult
Solution Approach 1:
The patent changes the physical state parameters of the pharmaceutical composition during processing. By controlling temperature, pressure, and flow rate parameters during direct extrusion, the system can achieve high API concentrations without requiring the filament to maintain specific mechanical strength. The composition is extruded in a softened state and deposited layer-by-layer, allowing high drug loadings that would be impossible in solid filament form
Solution Approach 2:
The system utilizes phase transitions of the polymer matrix during extrusion and deposition. The pharmaceutical composition is heated to transition the polymer from solid to softened/melted state during extrusion, allowing high API content to be processed. Upon deposition and cooling, the material solidifies to form the printed structure, eliminating the need for the filament to maintain mechanical integrity at high API loadings
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables the printing of pharmaceutical dose forms with higher API concentrations and a broader range of formulation ingredients, overcoming limitations of existing methods by directly extruding and dispensing pharmaceutical compositions.
Implementation Method 1
The material is fed through as a solid filament (having specific dimensional and mechanical properties) and is mobilised as it is heated and melted thus enabling the material to flow through a nozzle
Implementation Method 2
The material exiting the nozzle is deposited in sequential layers onto a surface where it solidifies to create the 3D object
Data Source
Figure 1~2
Figure 3~5
Figure 6~7
AI summary
A dispensing apparatus (200) configured for dispensing a composition (111) comprises at least one inlet (251) configured for receiving a composition (111); at least one outlet (252) configured for dispensing the composition (111); at least one directional flow valve (250) located between the at least one inlet (251) and the at least one outlet (252); and at least one regulating module (260) in fluid communication with a respective directional flow valve (250), wherein the at least one regulating module (260) is configured to control and/or regulate flow of the composition (111) to at least one outlet (252).